GLP-1 lawsuit tracker
Over $6 billion in active GLP-1 litigation is pending in 2026. It falls into three groups:
- Gastroparesis injury claims against Novo Nordisk.
- 130+ patent infringement lawsuits against compounders.
- FTC investigations into deceptive marketing.
This tracker monitors major legal developments that may affect GLP-1 patients and providers.
Last updated: August 2026. This is a summary of publicly reported litigation, not legal advice.
Active Cases We're Tracking in 2026
Ozempic/Wegovy Gastroparesis & GI Injury Claims
MDL ActiveThousands of individual claims alleging Ozempic and Wegovy caused severe gastroparesis (stomach paralysis), bowel obstruction, and other serious GI injuries beyond what was disclosed in prescribing information. Consolidated into multibellwether litigation.
Novo Nordisk vs. Compounding Pharmacies (Patent Infringement)
Active across 40+ statesNovo Nordisk filed 130+ lawsuits against compounding pharmacies selling compounded semaglutide, alleging patent infringement and patient safety violations. Many resulted in settlements or pharmacy closures.
Eli Lilly vs. Compounding Pharmacies (Tirzepatide)
ActiveEli Lilly pursuing similar patent enforcement actions against pharmacies compounding tirzepatide (the active ingredient in Mounjaro/Zepbound) after FDA ruled tirzepatide was never in shortage.
FTC and States v. Hims & Hers Health, Inc.
PendingOn July 29, 2026 the Federal Trade Commission, joined by the Utah Division of Consumer Protection and the People of the State of California acting through Los Angeles County Counsel Dawyn R. Harrison, filed a Complaint for Permanent Injunction, Monetary Judgment, Civil Penalty Judgment, and Other Relief against Hims & Hers Health, Inc. The complaint alleges the company fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling them they will be able to consult a medical provider first; that it made subscriptions difficult to cancel; and that it shared consumers' health information with Meta, Snap and other third parties despite claiming its services keep that information private. Case status is Pending. These are allegations that have not been proven in court, and the company has not been found liable. Hims and Hers are the two consumer brands of this defendant, and both of our review pages carry the same disclosure.
Source: FTC Legal Library case record
FTC Enforcement Against Deceptive GLP-1 Marketing
Ongoing investigationsThe FTC is investigating multiple telehealth companies for deceptive marketing practices related to GLP-1 medications, including false efficacy claims, hidden pricing, and misleading before/after imagery.
State AG Actions Against Compounded GLP-1 Sellers
Active in 12+ statesState attorneys general in Texas, California, Florida, and 9+ other states pursuing enforcement against companies selling compounded GLP-1 medications without proper licensing or making unsubstantiated health claims.
What This Means for Patients
If you experienced severe GI side effects
If you developed gastroparesis, severe stomach paralysis, bowel obstruction, or other serious GI injuries while taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may be eligible to join the MDL.
Consult a personal injury attorney specializing in pharmaceutical litigation.
If your compounded medication was discontinued
Many compounding pharmacies shut down or stopped offering semaglutide after FDA enforcement and Novo Nordisk lawsuits.
If your provider can no longer supply your medication, see our provider rankings for legitimate alternatives offering brand-name or reformulated compounded options.
How to verify your provider
Use our Safety Checker to review the public warning-letter and pharmacy-disclosure records we have collected. It is a non-exhaustive research aid, not proof of FDA compliance or medical safety.
Where to go next
Not sure which provider is safe and right for you? Take our 2-minute match quiz, or explore the safety resources below.